vaccine program News
-
Results from Positive Phase 2 Study of NovaDigm Therapeutics` NDV-3A Vaccine Against Candida Published in Clinical Infectious Diseases
NovaDigm Therapeutics, a company developing innovative immunotherapeutics and preventative vaccines for fungal and bacterial infections, today announced the publication of data from a Phase 2a study of its NDV-3A vaccine program in the journal Clinical Infectious Diseases. The data demonstrate that a single dose of NDV-3A with alum adjuvant was safe, well-tolerated, immunogenic and efficacious, ...
-
AMA Honors Government Service, Dedication to Health Care
The American Medical Association (AMA) today announced the seven recipients of the 2015 Dr. Nathan Davis Award for Outstanding Government Service – the highest award for elected officials and government employees from the nation's largest physician organization. The award, named for the founding father of the AMA, recognizes elected and career officials in federal, state or municipal ...
-
Vaxxinity to Participate at the Jefferies Healthcare Conference
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, President and Chief Executive Officer of Vaxxinity, will participate in a fireside chat at the Jefferies Healthcare Conference, being held in New York, NY on Thursday, June 9, 2022 at 11:30 a.m. ET. A live webcast of the fireside chat can be ...
By Vaxxinit
-
Vaxxinity to Participate at the Bank of America Securities 2022 Healthcare Conference
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, President and Chief Executive Officer of Vaxxinity, will participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference, being held in Las Vegas, Nevada on Thursday, May 12, 2022 at 10:40 a.m. PT. A live webcast of ...
By Vaxxinit
-
ICMA and National League of Cities CEOs Encourage Trust in Health & Safety of COVID Vaccine
With the recent approval of a COVID-19 vaccine, there is great hope that there will soon be an end to what is arguably the most painful and deadliest public health crisis in our country’s history. While a mass vaccination program, now underway, will bring healing to a nation that has witnessed more than 300,000 COVID deaths, medical authorities tell us that we are still months away from ...
-
Implementing “Sysmex Gives Back Day”, a Group-wide Social Contribution Activities
Sysmex Group, observing a unified global theme of “Aim for a Healthier Society” in line with its Policy on Corporate Citizenship Activities and Philanthropy, promotes social contribution activities with the whole group acting in concert. Based on that theme, we implemented “Sysmex Gives Back Day”, which comprises a program of activities from October through January. ...
-
Medical Refrigerators for Storing Covid-19 Vaccine
And it happened – on December 21, the European Commission approved the conditional approval of the COVID-19 vaccine developed by Pfizer and BioNTech. The decision was based on the opinion of the Committee for Medicinal Products for Human Use at the European Medicines Agency. We’ve been all waiting impatiently for this decision – it would probably not be an ...
-
Virometix Broadens Senior Leadership Team with Three Key Appointments
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, today announced the expansion of its leadership team with the appointment of a Chief Scientific Officer and two additional Board members. Virometix filled a vacancy in its management team with the ...
By Virometix AG
-
ARTES joins global combat against Corona
ARTES Biotechnology, the German-based biotech company specializing in process development for recombinant vaccines, entered development of SARS-CoV-2 vaccine candidates based on its virus-like particle (VLP) based platform technologies METAVAX® and SplitCore. METAVAX® is the company´s platform for the development of vaccines built on enveloped virus-like particle nanostructures ...
-
As Companies Work Around the Clock to Address COVID-19, BIO Outlines Key Policy Priorities to Prevent the Next Pandemic
The Senate Committee on Health, Education, Labor and Pensions, chaired by Senator Lamar Alexander, will hold an important hearing today to examine lessons learned from the current global health crisis to help make sure we are better prepared for the next pandemic. Public health expert and patient advocate, Dr. Julie Gerberding, will join the discussion, alongside former top policy leaders. The ...
-
Royal Government of Bhutan, Merck and Australian Cervical Cancer Foundation partner on vaccination program with GARDASIL(R) for girls and young women of Bhutan
The Royal Government of Bhutan, Merck (which is known as MSD outside the United States and Canada) and the Australian Cervical Cancer Foundation (ACCF) today launched a national vaccination program with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls and young women in Bhutan. In an effort to reduce the burden of cervical cancer, ...
-
YourBio Health launches nearly painless, at-home COVID-19 antibody test
YourBio Health, formerly Seventh Sense Biosystems, Inc., developers of the world’s first push-button blood collection device, announced the launch of its website where UK consumers can order a convenient, easy to use, nearly painless and accurate COVID-19 antibody test. “We’re happy to launch our COVID-19 antibody test service to UK consumers today,” said Stephen Hahn, ...
-
INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the first participant was dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, in Ghana. The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute ...
-
Merck significantly expands its patient assistance program offerings to provide access to more medicines for people in need
Today, Merck announced that it has significantly expanded the number of Merck medicines available through its Merck Helps™ patient assistance programs, which include the Merck Patient Assistance Program, the Merck Vaccine Patient Assistance Program, the ACT Program for Oncology and Hepatitis C medicines, and the SUPPORT Program for HIV/AIDS medicines. The Merck Helps programs provide Merck ...
-
Thermo Fisher Scientific`s Response to COVID-19 Continues to Expand to Support Development and Production of Therapeutics and Vaccines
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, continues to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments. The company is now supporting more than 200 of these projects ...
-
Lumen Bioscience Announces Publication in NPJ Vaccines of Preclinical Data Demonstrating Needle Free, Spirulina-produced Vaccination Offering Protection Against Malaria
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced the publication of data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research, conducted in collaboration with the University of Washington, was published in the peer-reviewed journal, Nature Partner ...
-
Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Disease
Vaxxinity, Inc. (Nasdaq: VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease. “We are excited that the FDA has granted UB-311 Fast Track ...
By Vaxxinit
-
Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch
Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that its COVID-19 vaccine candidate has been successfully coated onto Zosano Pharma Corporation’s (NASDAQ:ZSAN) proprietary ...
-
Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape
Vaccitech plc (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced it will host a virtual Key Opinion Leader (“KOL”) event on VTP-300, in development as a key component of a functional cure therapy for chronic hepatitis B (CHB) infection, and the broader CHB therapeutics ...
-
Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate
Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a company addressing major global infectious disease threats through the development of fully synthetic CD8+ T-Cell Adaptive Vaccines, today announces that it has entered into an agreement with ATCC to progress preclinical development of its Yellow Fever booster vaccine program. ATCC is a non-profit ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you